United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

United Therapeutics Corp. (UTHR) PT Raised to $660 at TD Cowen, 'remains a top pick'

March 30, 2026 8:33 AM EDT

TD Cowen analyst Joseph Thome raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $660.00 (from $575.00) while maintaining a Buy rating.

The analyst comments "UTHR announced that the second Ph. III study of Tyvaso for IPF (TETON-1) hit the primary... More